Genetic Selection Pressure on TLR9 Gene Increases Individual Susceptibility to Systemic Inflammatory Disease: A Case Study of Kano State Population
DOI:
https://doi.org/10.23918/eajse.v10i2p1Keywords:
TLR9 Gene, Inflammatory disease, Polymorphism, Population, PCR-RFLPAbstract
Toll-like receptor 9 (TLR9) may recognize and generate an immunological response to DNA double-strand; therefore, its link with experimental and serological lupus symptoms must be investigated. Genetic data on the normal frequencies of the TLR9 (rs187084) polymorphism may make it difficult to choose an adequate sample size for case-control association studies. This study investigated how TLR9 (rs187084) polymorphism is typically distributed among the people living in Kano, Nigerians. TLR9 (rs187084) polymorphism was examined in a sample of 315 individuals using the polylmerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The mutant allele was more common (67%) and gender-independent. The gradual incidence of changed alleles in both identities suggests the population was chosen to survive tuberculosis (TB) and malaria. Though increased TLR9 expression is protective against infections, it might likewise play a part in the development of inflammatory disorders. The high frequency of TLR9 (rs187084) over-expression in Kano State residents may be the result of genetic adaptation to the state's common infectious and parasitic diseases. This is thought to be the outcome of interactions among genetic factors and the terrain. Systemic lupus erythematosus (SLE) and other autoimmune disorders have been linked to this genetic plasticity. Sample sizes for future case-control studies can be determined using the current data. However, to further understand the link between the TLR9-rs187084 variation and the risk of systemic inflammatory diseases, functional investigations might be undertaken.
References
[1] Habib YJ, Zhang Z. The involvement of crustaceans toll-like receptors in pathogen
recognition. Fish & shellfish immunology, 2020. 102: p. 169-176.
https://doi.org/10.1016/j.fsi.2020.04.035
[2] El-Zayat SR, Sibaii H, Mannaa FA. Toll-like receptors activation, signaling, and targeting: an
overview. Bulletin of the National Research Centre, 2019. 43(1): p. 1-
12. https://doi.org/10.1186/s42269-019-0227-2
[3] Nie L, Cai S-Y, Shao J-Z, Chen J. Toll-like receptors, associated biological roles, and
signaling networks in non-mammals. Frontiers in immunology, 2018. 9: p. 1523.
https://doi.org/10.3389%2Ffimmu.2018.01523
[4] Behzadi P, García-Perdomo HA, Karpiński TM. Toll-like receptors: general molecular and
structural biology. Journal of Immunology Research, 2021. 2021: p. 1-
21. https://doi.org/10.1155/2021/9914854.
[5] Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell, 2020. 180(6):
p. 1044-1066. https://doi.org/10.1016/j.cell.2020.02.041.
[6] Yusuf J, Kaliyaperumal D, Jayaraman M, Ramanathan G, Devaraju P. Genetic selection
pressure in TLR9 gene may enforce risk for SLE in Indian Tamils. Lupus, 2017. 26(3): p. 307-
310. https://doi.org/10.1177/0961203316659151.
[7] Kang JY, Lee J-O. Structural biology of the Toll-like receptor family. Annual review of
biochemistry, 2011. 80: p. 917-941. https://doi.org/10.1146/annurev-biochem-052909-141507.
[8] Sameer AS, Nissar S. Toll-like receptors (TLRs): structure, functions, signaling, and role of
their polymorphisms in colorectal cancer susceptibility. BioMed Research International, 2021.
2021. https://doi.org/10.1155/2021/1157023
[9] Thada S, Valluri V, Gaddam S. Influence of Toll‐like receptor gene polymorphisms to
tuberculosis susceptibility in humans. Scandinavian journal of immunology, 2013. 78(3): p.
221-229. https://doi.org/10.1111/sji.12066.
[10] Trejo-De La O A, Hernández-Sancén P, Maldonado-Bernal C. Relevance of single-nucleotide
polymorphisms in human TLR genes to infectious and inflammatory diseases and cancer.
Genes & Immunity, 2014. 15(4): p. 199-209. https://doi.org/10.1038/gene.2014.10.
[11] Lazarus R, Klimecki WT, Raby BA, Vercelli D, Palmer LJ, Kwiatkowski DJ. Singlenucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise
linkage disequilibrium, and haplotypes in three US ethnic groups and exploratory case–control
disease association studies. Genomics, 2003. 81(1): p. 85-91. https://doi.org/10.1016/S0888-
7543(02)00022-8.
[12] Noguchi E, Nishimura F, Fukai H, Kim J, Ichikawa K, Shibasaki M. An association study of
asthma and total serum immunoglobin E levels for Toll‐like receptor polymorphisms in a
Japanese population. Clinical & Experimental Allergy, 2004. 34(2): p. 177-
183.https://doi.org/10.1111/j.1365-2222.2004.01839.x.
[13] Berghöfer B, Frommer T, König I, Ziegler A, Chakraborty T, Bein G. Common human Toll‐
like receptor 9 polymorphisms and haplotypes: association with atopy and functional
relevance. Clinical & Experimental Allergy, 2005. 35(9): p. 1147-1154.
https://doi.org/10.1111/j.1365-2222.2005.02325.x.
[14] Hamann L, Glaeser C, Hamprecht A, Gross M, Gomma A, Schumann RR. Toll-like receptor
(TLR)-9 promotor polymorphisms and atherosclerosis. Clinica Chimica Acta, 2006. 364(1-2):
p. 303-307. https://doi.org/10.1016/j.cca.2005.07.017.
[15] Tao K, Fujii M, Tsukumo S-i, Maekawa Y, Kishihara K, Kimoto Y. Genetic variations of Tolllike receptor 9 predispose to systemic lupus erythematosus in Japanese population. Annals of
the rheumatic diseases, 2007. https://doi.org/10.1136/ard.2006.065961.
[16] De Jager PL, Richardson A, Vyse TJ, Rioux JD. Genetic variation in toll‐like receptor 9 and
susceptibility to systemic lupus erythematosus. Arthritis & Rheumatism, 2006. 54(4): p. 1279-
1282. https://doi.org/10.1002/art.21755.
[17] Hur JW, Shin H, Park B, Kim L, Kim SY, Bae SC. Association study of Toll‐like receptor 9
gene polymorphism in Korean patients with systemic lupus erythematosus. Tissue Antigens,
2005. 65(3): p. 266-270. https://doi.org/10.1111/j.1399-0039.2005.00374.x.
[18] Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K. Two stage genome–wide
search in inflammatory bowel disease provides evidence for susceptibility loci on
chromosomes 3, 7 and 12. Nature genetics, 1996. 14(2): p. 199-202.
https://doi.org/10.1038/ng1096-199.
[19] Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T. Deficient hostbacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly
polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut, 2004. 53(7): p.
987. https://doi.org/10.1136/gut.2003.030205.
[20] Lammers K, Ouburg S, Morre S, Crusius J, Gionchetti P, Rizzello F. Combined carriership of
TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing
pouchitis. World Journal of Gastroenterology, 2005. 11(46): p. 7323.
https://doi.org/10.3748/wjg.v11.i46.7323.
[21] Kikuchi K, Lian Z-X, Kimura Y, Selmi C, Yang G-X, Gordon SC. Genetic polymorphisms of
toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in
primary biliary cirrhosis. Journal of autoimmunity, 2005. 24(4): p. 347-352.
https://doi.org/10.1016/j.jaut.2005.03.002.
[22] Mukherjee S, Huda S, Sinha Babu SP. Toll‐like receptor polymorphism in host immune
response to infectious diseases: A review. Scandinavian journal of immunology, 2019. 90(1): p.
e12771. https://doi.org/10.1111/sji.12771.
[23] Kutikhin, A.G. Association of polymorphisms in TLR genes and in genes of the Toll-like
receptor signaling pathway with cancer risk. Human immunology, 2011. 72(11): p. 1095-1116.
https://doi.org/10.1016/j.humimm.2011.07.307.
[24] Cui J, Chen Y, Wang HY, Wang R-F. Mechanisms and pathways of innate immune activation
and regulation in health and cancer. Human vaccines & immunotherapeutics, 2014. 10(11): p.
3270-3285. https://doi.org/10.4161/21645515.2014.979640.
[25] Skevaki C, Pararas M, Kostelidou K, Tsakris A, Routsias J. Single nucleotide polymorphisms
of Toll-like receptors and susceptibility to infectious diseases. Clinical & Experimental
Immunology, 2015. 180(2): p. 165-177. https://doi.org/10.1111/cei.12578
[26] Selvaraj P, Harishankar M, Singh B, Jawahar M, Banurekha V. Toll-like receptor and TIRAP
gene polymorphisms in pulmonary tuberculosis patients of South India. Tuberculosis, 2010.
90(5): p. 306-310. https://doi.org/10.1016/j.tube.2010.08.001
[27] Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like
receptor 9 controls anti-DNA autoantibody production in murine lupus. The Journal of
experimental medicine, 2005. 202(2): p. 321-331.
https://doi.org/10.1084/jem.20050338.
[28] Omar AH, Yasunami M, Yamazaki A, Shibata H, Ofori MF, Akanmori BD. Toll-like receptor 9
(TLR9) polymorphism associated with symptomatic malaria: a cohort study. Malaria journal,
2012. 11: p. 1-10. https://doi.org/10.1186/1475-2875-11-168.
[29] Zhang L, Qin H, Guan X, Zhang K, Liu Z. The TLR9 gene polymorphisms and the risk of
cancer: evidence from a meta-analysis. PloS one, 2013. 8(8): p. e71785.M
https://doi.org/10.1371/journal.pone.0071785
[30] Ramachandran R, Sharma V, Rathi M, Yadav A, Sharma A, Kohli H. Association between1486 T> C and+ 1174 G> A single nucleotide polymorphisms in TLR9 gene and severity of
lupus nephritis. Indian journal of nephrology, 2012. 22(2): p. 125.
https://doi.org/10.4103/0971-4065.97133.
[31] Tao K, Fujii M, Tsukumo S-i, Maekawa Y, Kishihara K, Kimoto Y. Genetic variations of Tolllike receptor 9 predispose to systemic lupus erythematosus in Japanese population. Annals of
the rheumatic diseases, 2007. 66(7): p. 905-909. https://doi.org/10.1136/ard.2006.065961.
[32] Fumagalli M, Sironi M. Human genome variability, natural selection and infectious diseases.
Current opinion in immunology, 2014. 30: p. 9-16. https://doi.org/10.1016/j.coi.2014.05.001.
[33] Zhang J, Zhu Q, Meng F, Lei H, Zhao Y. Association study of TLR-9 polymorphisms and
systemic lupus erythematosus in northern Chinese Han population. Gene, 2014. 533(1): p.
385-388. https://doi.org/10.1016/j.gene.2013.08.051.
[34] Rupasree Y, Naushad S, Rajasekhar L, Uma A, Kutala V. Association of TLR4 (D299G,
T399I), TLR9− 1486T> C, TIRAP S180L and TNF-α promoter (− 1031,− 863,− 857)
polymorphisms with risk for systemic lupus erythematosus among South Indians. Lupus, 2015.
24(1): p. 50-57. https://doi.org/10.1177/0961203314549792.
[35] Devaraju P, Gulati R, Antony PT, Mithun C, Negi VS. Susceptibility to SLE in South Indian
Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes. Molecular
immunology, 2015. 64(1): p. 123-126. https://doi.org/10.1016/j.molimm.2014.11.005.
[36] Obermoser G, Pascual V. The interferon-α signature of systemic lupus erythematosus. Lupus,
2010. 19(9): p. 1012-1019. https://doi.org/10.1177/0961203310371161.
[37] Lenert, P.S., Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and
autoreactive B cells as a therapy for lupus. Arthritis research & therapy, 2006. 8: p. 1-11.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Eurasian J. Sci. Eng is distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY-4.0) https://creativecommons.org/licenses/by/4.0/
